Knowledge on the pathophysiology of irritable bower syndrome has evolved, b
eginning with disturbances in motility to visceral hypersensitivity, and ul
timately to alterations in brain-gut bidirectional communication, where neu
rotransmitters such as serotonin play a key role. Recently, a multicomponen
t disease model that integrates at these alterations was proposed. This mod
el is divided into physiological, cognitive, emotional and behavioral compo
nents that explain the gastrointestinal as well as the constitutional sympt
oms. In recent years there has been an explosion of research together with
new developments in pharmacological treatments for IBS that support each co
mponent of this model. This review presents recent data in favor of these a
lterations in IBS.